Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2

Interventions

Gemcitabine 56pembrolizumab 50Cisplatin 43Magnetic Resonance Spectroscopy 27enfortumab vedotin 22Specimen Handling 22Nivolumab 22Cystectomy 18durvalumab 16Carboplatin 16avelumab 15Mitomycin 14atezolizumab 13Docetaxel 13Cystoscopy 12Fluorouracil 11Radiation 9Transurethral Resection of Bladder 8Radiotherapy 8Ipilimumab 8sacituzumab govitecan 7Standard of Care 7Radiosurgery 7Paclitaxel 7Immunoglobulin G 7Disulfides 7erdafitinib 6cemiplimab 6Surveys and Questionnaires 6Surgical Procedures, Operative 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × 5-aminolevulinic acid hexyl ester × 1 year × Clear all
NCT02660645 2025-12-18

BLCCR

Photocure

Recruiting
4,400 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University

Phase 3 Recruiting
200 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡